Ligand Pharmaceuticals Inc (LGND) News Headlines

▮ More

Date

Headline

5/4/2023 5:10:57 PM Ligand Pharmaceuticals Inc Q1 Earnings Summary

5/4/2023 5:05:01 PM Ligand Pharma Q1 EPS $2.33 Vs. Loss $0.91 Year Ago

2/22/2023 4:52:06 PM Ligand Pharma Q4 Loss/share $1.04 Vs. Loss $0.32 Year Ago

2/22/2023 4:43:28 PM Ligand Pharmaceuticals Inc Q4 Earnings Summary

2/16/2023 8:05:18 AM Sermonix And Quantum To Evaluate Lasofoxifene In Ongoing I-SPY 2 Trial In Estrogen Receptor-positive Invasive Cancer

1/6/2023 8:34:50 AM Ligand Pharma's Partner Novan Submits NDA For Berdazimer Gel For Treatment Of Molluscum

1/6/2023 8:08:40 AM Ligand's Partner Novan Submits NDA To FDA For Berdazimer Gel, 10.3% For Molluscum Contagiosum Treatment

12/13/2022 9:05:20 AM Ligand Pharma Guides FY23 EPS Above View, But Revenue Shy Of Estimates

12/13/2022 8:37:57 AM Ligand Pharma Expects FY23 Total Core Revenue To Be $118 Mln To $122 Mln

12/5/2022 7:21:11 AM Ligand Pharma CEO John Higgins Retires; Todd Davis To Succeed Higgins As CEO

12/5/2022 7:08:40 AM Ligand Pharma CEO John Higgins Retires; Names Todd Davis CEO

11/7/2022 5:09:29 PM Ligand Pharmaceuticals Inc (LGND) Has Raised Its 2022 Revenue Estimate To $184 - $189 Mln From $133 - $146 Mln

11/7/2022 5:08:30 PM Ligand Pharmaceuticals Inc Q3 Profit Decreases, but beats estimates

11/7/2022 4:47:40 PM Ligand Pharma Q3 EPS $0.02 Vs. $0.80 Year Ago

11/7/2022 3:00:10 PM Ligand Pharmaceuticals Q3 22 Earnings Conference Call At 4:30 PM ET

11/1/2022 4:17:59 PM Ligand Completes OmniAb Spin-Off

10/26/2022 8:27:22 AM Ligand' License Partner Janssen Received FDA Approval For Tecvayli For Refractory Multiple Myeloma

10/26/2022 8:06:27 AM Ligand Says Janssen Gets Approval For TECVAYLI For Patients With Relapsed Or Refractory Multiple Myeloma

8/24/2022 9:48:30 PM Ligand : Janssen's Tecvayli Gets Conditional Approval In Europe For R/R Multiple Myeloma Treatment

6/29/2022 4:07:16 PM Ligand Pharmaceuticals Appoints Jason Haas To Its Board Of Directors